Internal Medicine, Infectious Disease · Baltimore, MD
NPI
1902062755
Since 2008
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
22 S Greene St
Baltimore, MD, 21201
Phone (410) 328-4613
Groups this clinician bills Medicare through
Medicare paid, 2024
$32K
365 services
Medicare patients, 2024
150
Average age 64
Drug cost, 2024
$1.5M
1,254 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Patrick A Ryscavage was code 99233 (hospital e&m - subsequent), 145 times for 56 patients. In total Patrick A Ryscavage billed 365 services in 12 codes, and Medicare paid $32K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-07-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 145 | 56 | $95.87 | $14K |
| 99214 Office E&M - Established | Facility | 83 | 53 | $67.26 | $5,583 |
| 99232 Hospital E&M - Subsequent | Facility | 58 | 24 | $64.11 | $3,719 |
| 99223 Hospital E&M - Initial | Facility | 41 | 38 | $140.48 | $5,760 |
| 99222 Hospital E&M - Initial | Facility | 12 | 12 | $106.17 | $1,274 |
By year: 2022 $36K for 433 services; 2023 $41K for 462 services; 2024 $32K for 365 services.
Medicare prescription drug claims, 2024
In 2024, the drug Patrick A Ryscavage prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 79 prescriptions and refills. In total Patrick A Ryscavage wrote 1,254 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 79 | 79 | 14 | $302K |
| Tivicay Dolutegravir Sodium | 77 | 77 | Under 11 | $164K |
| Descovy Emtricitabine/Tenofov Alafenam | 76 | 84 | Under 11 | $170K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 67 | 67 | Under 11 | $249K |
| Dovato Dolutegravir Sodium/Lamivudine | 66 | 66 | 11 | $196K |
| Atorvastatin Calcium Generic | 39 | 41 | Under 11 | $71.12 |
| Famotidine Generic | 38 | 38 | Under 11 | $99.33 |
| Metoprolol Succinate Generic | 34 | 46 | Under 11 | $251 |
| Losartan Potassium Generic | 32 | 36 | Under 11 | $161 |
| Rosuvastatin Calcium Generic | 32 | 37 | Under 11 | $377 |
| Ketoconazole Generic | 28 | 28 | Under 11 | $349 |
| Pifeltro Doravirine | 26 | 26 | Under 11 | $44K |
| Abacavir-Lamivudine Abacavir Sulfate/Lamivudine | 25 | 25 | Under 11 | $21K |
| Amlodipine Besylate Generic | 25 | 25 | Under 11 | $11.12 |
| Ventolin Hfa Albuterol Sulfate | 24 | 24 | Under 11 | $1,347 |
Brand drugs: 572 claims; generic drugs: 652 claims; opioid claims: 18.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Patrick A Ryscavage were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.